About Echo IQ Ltd
Echo IQ Ltd is a health AI company specializing in AI-powered solutions for detecting structural heart disease, with a primary focus on aortic stenosis (AS). The company's flagship product, EchoSolv AS, is an FDA-cleared artificial intelligence decision support algorithm that analyzes routine echocardiographic measurements to identify patients at increased probability of severe aortic stenosis and mortality risk. Unlike traditional approaches that rely on image analysis, Echo IQ's technology works exclusively with the numerical measurements already collected during standard echocardiograms, providing measurement-based decision support that delivers results in seconds at the point of clinical decision. The platform was developed using one of the world's largest echocardiographic measurement datasets, comprising over 200 million measurements, and is designed to complement clinician review without replacing clinical judgment. The company's mission is to leverage AI technology to enhance the identification of structural heart disease and support earlier, more accurate detection of life-threatening conditions. Their innovations are designed to optimize efficiency, consistency, throughput, and turnaround time while fitting seamlessly into existing clinical workflows with minimal disruption. Echo IQ's approach aims to reduce bias in detection, particularly addressing underdiagnosis in women, and to identify patients who might benefit from more definitive treatment or specialist care. Echo IQ's technology is supported by extensive clinical research published in leading cardiology journals, demonstrating the algorithm's effectiveness in identifying severe AS cases that may be missed by traditional guideline-based approaches. The company serves healthcare systems, cardiology practices, and echocardiography labs, with a focus on improving patient outcomes through AI-enhanced cardiac diagnostics.
Mission & Story
Mission
We leverage AI technology to enhance the identification of structural heart disease. Our mission is to help support earlier, more accurate detection of life-threatening but often treatable conditions.
Clinical Focus
Medical conditions and clinical areas addressed by Echo IQ Ltd.
Who It Serves
Milestones & Awards
Recent Milestones
FDA clearance for EchoSolv AS. Multiple clinical validation studies published in 2023-2024 in leading cardiology journals including JACC Advances and American Heart Journal Plus.
Company Details
- Headquarters
- Sydney, NSW, Australia
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 64 →
AccurKardia
AI-powered platform for cardiovascular disease detection and cardiac risk assessment.
Acorai
AI platform for cardiovascular disease detection and cardiac risk assessment.
Aisap
11-50 employees
AISAP provides FDA-cleared AI-powered diagnostic algorithms embedded in an operating system for point-of-care ultrasound (POCUS) devices. The platform enables rapid, expert-level cardiac imaging interpretation at the bedside, helping physicians detect structural heart disease early and make faster clinical decisions across hospitals, clinics, and screening programs.
AliveCor
AliveCor develops FDA-cleared, AI-powered ECG devices and software platforms for cardiac monitoring. The company offers portable ECG solutions ranging from consumer personal devices to clinical-grade 12-lead systems, serving patients, healthcare providers, biopharma companies, and health systems with remote and connected cardiac care.
Anumana AI
series c · 175 employees
Anumana AI develops and delivers AI-driven ECG algorithms to enable early diagnosis and intervention for cardiovascular conditions.
Artrya
11-50 employees
Artrya develops AI-powered solutions for rapid assessment of chest pain patients in emergency and primary care settings. The company's technology analyzes coronary computed tomography angiography (CCTA) to detect arterial plaque and stratify patient risk within minutes.
Bay Labs
Bay Labs is a health AI company focused on cardiology and cardiovascular health. The company's website is currently under construction with limited public information available.
BunkerHill Health
Bunkerhill Health provides Carebricks, an AI-powered platform that enables health systems to design, deploy, and operationalize AI agents across clinical and operational workflows. The platform reasons across patient data and automates actions within existing EHR systems.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.